PubMed:17020975 JSONTXT

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":0,"end":6},"obj":"gene:6041"},{"id":"T1","span":{"begin":42,"end":57},"obj":"disease:C0376358"},{"id":"T2","span":{"begin":0,"end":6},"obj":"gene:6041"},{"id":"T3","span":{"begin":42,"end":57},"obj":"disease:C0600139"},{"id":"T4","span":{"begin":138,"end":144},"obj":"gene:6041"},{"id":"T5","span":{"begin":309,"end":324},"obj":"disease:C0600139"},{"id":"T6","span":{"begin":138,"end":144},"obj":"gene:6041"},{"id":"T7","span":{"begin":309,"end":324},"obj":"disease:C0376358"},{"id":"T8","span":{"begin":138,"end":144},"obj":"gene:6041"},{"id":"T9","span":{"begin":196,"end":211},"obj":"disease:C0600139"},{"id":"T10","span":{"begin":138,"end":144},"obj":"gene:6041"},{"id":"T11","span":{"begin":196,"end":211},"obj":"disease:C0376358"},{"id":"T12","span":{"begin":452,"end":458},"obj":"gene:6041"},{"id":"T13","span":{"begin":468,"end":483},"obj":"disease:C0600139"},{"id":"T14","span":{"begin":452,"end":458},"obj":"gene:6041"},{"id":"T15","span":{"begin":468,"end":483},"obj":"disease:C0376358"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"},{"id":"R6","pred":"associated_with","subj":"T10","obj":"T11"},{"id":"R7","pred":"associated_with","subj":"T12","obj":"T13"},{"id":"R8","pred":"associated_with","subj":"T14","obj":"T15"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis.\nPURPOSE: Studies revealing conflicting results on the role of RNASEL polymorphisms Glu265X, Arg462Gln, and Asp541Glu on prostate cancer risk led us to perform a meta-analysis to investigate the association of these polymorphisms and prostate cancer risk.\nEXPERIMENTAL DESIGN: Relevant studies were selected by searching PubMed from January 1996 to August 2005 using keywords \"RNASEL gene AND prostate cancer.\" For each study, odds ratio (OR) with 95% confidence interval (95% CI) was calculated to estimate the gene effect. Pooled estimates of the OR were computed using the random effects model.\nRESULTS: Ten studies were included in the meta-analysis. The overall results suggested no major influence of these variants on prostate cancer risk. However, analysis of the Asp541Glu polymorphism by ethnic populations showed that Asp/Glu (familial cases versus control: OR, 1.38; 95% CI, 1.04-1.82; sporadic cases versus control: OR, 1.26; 95% CI, 1.07-1.48; prostate cancer versus control: OR, 1.29; 95% CI, 1.12-1.48) and Asp/Glu + Glu/Glu (familial cases versus control: OR, 1.37; 95% CI, 1.10-1.70; sporadic cases versus control: OR, 1.24; 95% CI, 1.07-1.44; prostate cancer versus control: OR, 1.27; 95% CI, 1.13-1.44) increased prostate cancer risk in Caucasians, thus suggesting a dominant model for the Glu variant.\nCONCLUSIONS: Compared with the genotype Asp/Asp, the Glu variant at the Asp541Glu polymorphism increases prostate cancer risk by \u003c2-fold in Caucasians, regardless of family history of the disease. This suggests that genuine genetic effects of this polymorphism may account for only a part of prostate cancer in the Caucasian population."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":196,"end":211},"obj":"HP_0012125"},{"id":"T2","span":{"begin":205,"end":211},"obj":"HP_0002664"},{"id":"T3","span":{"begin":309,"end":324},"obj":"HP_0012125"},{"id":"T4","span":{"begin":318,"end":324},"obj":"HP_0002664"}],"text":"RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis.\nPURPOSE: Studies revealing conflicting results on the role of RNASEL polymorphisms Glu265X, Arg462Gln, and Asp541Glu on prostate cancer risk led us to perform a meta-analysis to investigate the association of these polymorphisms and prostate cancer risk.\nEXPERIMENTAL DESIGN: Relevant studies were selected by searching PubMed from January 1996 to August 2005 using keywords \"RNASEL gene AND prostate cancer.\" For each study, odds ratio (OR) with 95% confidence interval (95% CI) was calculated to estimate the gene effect. Pooled estimates of the OR were computed using the random effects model.\nRESULTS: Ten studies were included in the meta-analysis. The overall results suggested no major influence of these variants on prostate cancer risk. However, analysis of the Asp541Glu polymorphism by ethnic populations showed that Asp/Glu (familial cases versus control: OR, 1.38; 95% CI, 1.04-1.82; sporadic cases versus control: OR, 1.26; 95% CI, 1.07-1.48; prostate cancer versus control: OR, 1.29; 95% CI, 1.12-1.48) and Asp/Glu + Glu/Glu (familial cases versus control: OR, 1.37; 95% CI, 1.10-1.70; sporadic cases versus control: OR, 1.24; 95% CI, 1.07-1.44; prostate cancer versus control: OR, 1.27; 95% CI, 1.13-1.44) increased prostate cancer risk in Caucasians, thus suggesting a dominant model for the Glu variant.\nCONCLUSIONS: Compared with the genotype Asp/Asp, the Glu variant at the Asp541Glu polymorphism increases prostate cancer risk by \u003c2-fold in Caucasians, regardless of family history of the disease. This suggests that genuine genetic effects of this polymorphism may account for only a part of prostate cancer in the Caucasian population."}

{"project":"DisGeNET5_variant_disease","denotations":[{"id":"17020975-1#83#92#geners486907","span":{"begin":168,"end":177},"obj":"geners486907"},{"id":"17020975-1#224#239#diseaseC0376358","span":{"begin":309,"end":324},"obj":"diseaseC0376358"},{"id":"17020975-1#224#239#diseaseC0600139","span":{"begin":309,"end":324},"obj":"diseaseC0600139"},{"id":"17020975-8#59#68#geners627928","span":{"begin":1470,"end":1479},"obj":"geners627928"},{"id":"17020975-8#92#107#diseaseC0376358","span":{"begin":1503,"end":1518},"obj":"diseaseC0376358"},{"id":"17020975-8#92#107#diseaseC0600139","span":{"begin":1503,"end":1518},"obj":"diseaseC0600139"}],"relations":[{"id":"83#92#geners486907224#239#diseaseC0376358","pred":"associated_with","subj":"17020975-1#83#92#geners486907","obj":"17020975-1#224#239#diseaseC0376358"},{"id":"83#92#geners486907224#239#diseaseC0600139","pred":"associated_with","subj":"17020975-1#83#92#geners486907","obj":"17020975-1#224#239#diseaseC0600139"},{"id":"59#68#geners62792892#107#diseaseC0376358","pred":"associated_with","subj":"17020975-8#59#68#geners627928","obj":"17020975-8#92#107#diseaseC0376358"},{"id":"59#68#geners62792892#107#diseaseC0600139","pred":"associated_with","subj":"17020975-8#59#68#geners627928","obj":"17020975-8#92#107#diseaseC0600139"}],"text":"RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis.\nPURPOSE: Studies revealing conflicting results on the role of RNASEL polymorphisms Glu265X, Arg462Gln, and Asp541Glu on prostate cancer risk led us to perform a meta-analysis to investigate the association of these polymorphisms and prostate cancer risk.\nEXPERIMENTAL DESIGN: Relevant studies were selected by searching PubMed from January 1996 to August 2005 using keywords \"RNASEL gene AND prostate cancer.\" For each study, odds ratio (OR) with 95% confidence interval (95% CI) was calculated to estimate the gene effect. Pooled estimates of the OR were computed using the random effects model.\nRESULTS: Ten studies were included in the meta-analysis. The overall results suggested no major influence of these variants on prostate cancer risk. However, analysis of the Asp541Glu polymorphism by ethnic populations showed that Asp/Glu (familial cases versus control: OR, 1.38; 95% CI, 1.04-1.82; sporadic cases versus control: OR, 1.26; 95% CI, 1.07-1.48; prostate cancer versus control: OR, 1.29; 95% CI, 1.12-1.48) and Asp/Glu + Glu/Glu (familial cases versus control: OR, 1.37; 95% CI, 1.10-1.70; sporadic cases versus control: OR, 1.24; 95% CI, 1.07-1.44; prostate cancer versus control: OR, 1.27; 95% CI, 1.13-1.44) increased prostate cancer risk in Caucasians, thus suggesting a dominant model for the Glu variant.\nCONCLUSIONS: Compared with the genotype Asp/Asp, the Glu variant at the Asp541Glu polymorphism increases prostate cancer risk by \u003c2-fold in Caucasians, regardless of family history of the disease. This suggests that genuine genetic effects of this polymorphism may account for only a part of prostate cancer in the Caucasian population."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"17020975-0#0#6#gene6041","span":{"begin":138,"end":144},"obj":"gene6041"},{"id":"17020975-0#42#57#diseaseC0376358","span":{"begin":849,"end":1048},"obj":"diseaseC0376358"},{"id":"17020975-0#42#57#diseaseC0600139","span":{"begin":849,"end":1048},"obj":"diseaseC0600139"}],"relations":[{"id":"0#6#gene604142#57#diseaseC0376358","pred":"associated_with","subj":"17020975-0#0#6#gene6041","obj":"17020975-0#42#57#diseaseC0376358"},{"id":"0#6#gene604142#57#diseaseC0600139","pred":"associated_with","subj":"17020975-0#0#6#gene6041","obj":"17020975-0#42#57#diseaseC0600139"}],"text":"RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis.\nPURPOSE: Studies revealing conflicting results on the role of RNASEL polymorphisms Glu265X, Arg462Gln, and Asp541Glu on prostate cancer risk led us to perform a meta-analysis to investigate the association of these polymorphisms and prostate cancer risk.\nEXPERIMENTAL DESIGN: Relevant studies were selected by searching PubMed from January 1996 to August 2005 using keywords \"RNASEL gene AND prostate cancer.\" For each study, odds ratio (OR) with 95% confidence interval (95% CI) was calculated to estimate the gene effect. Pooled estimates of the OR were computed using the random effects model.\nRESULTS: Ten studies were included in the meta-analysis. The overall results suggested no major influence of these variants on prostate cancer risk. However, analysis of the Asp541Glu polymorphism by ethnic populations showed that Asp/Glu (familial cases versus control: OR, 1.38; 95% CI, 1.04-1.82; sporadic cases versus control: OR, 1.26; 95% CI, 1.07-1.48; prostate cancer versus control: OR, 1.29; 95% CI, 1.12-1.48) and Asp/Glu + Glu/Glu (familial cases versus control: OR, 1.37; 95% CI, 1.10-1.70; sporadic cases versus control: OR, 1.24; 95% CI, 1.07-1.44; prostate cancer versus control: OR, 1.27; 95% CI, 1.13-1.44) increased prostate cancer risk in Caucasians, thus suggesting a dominant model for the Glu variant.\nCONCLUSIONS: Compared with the genotype Asp/Asp, the Glu variant at the Asp541Glu polymorphism increases prostate cancer risk by \u003c2-fold in Caucasians, regardless of family history of the disease. This suggests that genuine genetic effects of this polymorphism may account for only a part of prostate cancer in the Caucasian population."}